Back to News
Market Impact: 0.25
Solvonis raises £1.3m to fund three clinical programmes
Source: proactiveinvestors.co.uk
Company FundamentalsRegulation & LegislationCorporate Guidance & OutlookHealthcare & Biotech
Solvonis Therapeutics raised £1.3 million via a share placing, issuing 1.08 billion new shares at 0.12p each. The heavy share issuance suggests dilution risk, which may pressure near-term shareholder returns despite providing incremental funding for its addiction and psychiatric pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
SLVNF-0.25
More News
- Delta Air Lines cuts 2026 forecast on fuel surge, but CEO says demand is still strong
- Is AI the new China Shock?
- Why is T-Mobile stock tumbling today?
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- India calls JD Vance's comments about immigrants 'deeply offensive'
- The AI race may be decided by financing—not just better chips
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers